Garrison Financial Corp decreased its stake in Sanofi (NYSE:SNY) by 0.8% during the second quarter, according to its most recent filing with the SEC. The fund owned 8,295 shares of the company’s stock after selling 65 shares during the period. Garrison Financial Corp’s holdings in Sanofi were worth $397,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Guggenheim Capital LLC boosted its position in shares of Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares during the period. Capstone Asset Management Co. boosted its position in shares of Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock valued at $3,719,000 after buying an additional 4,635 shares during the period. Atria Investments LLC boosted its position in shares of Sanofi by 8.9% in the first quarter. Atria Investments LLC now owns 7,386 shares of the company’s stock valued at $334,000 after buying an additional 602 shares during the period. BLB&B Advisors LLC purchased a new position in shares of Sanofi during the first quarter valued at about $202,000. Finally, Cullinan Associates Inc. boosted its position in shares of Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares during the period. Hedge funds and other institutional investors own 9.96% of the company’s stock.
Shares of Sanofi (SNY) opened at 47.55 on Friday. The firm has a 50-day moving average price of $47.99 and a 200 day moving average price of $46.11. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24. The firm has a market capitalization of $119.42 billion, a price-to-earnings ratio of 11.23 and a beta of 0.88.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The business had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. On average, analysts anticipate that Sanofi will post $3.26 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/12/sanofi-sny-shares-sold-by-garrison-financial-corp.html.
SNY has been the topic of several research analyst reports. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Thursday, April 20th. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, BidaskClub lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $63.75.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.